A Systematic Review of the Safety of Lisdexamfetamine Dimesylate

@inproceedings{Coghill2014ASR,
  title={A Systematic Review of the Safety of Lisdexamfetamine Dimesylate},
  author={David R Coghill and Beatriz Caballero and Shaw Sorooshian and Richard Civil},
  booktitle={CNS drugs},
  year={2014}
}
BACKGROUND Here we review the safety and tolerability profile of lisdexamfetamine dimesylate (LDX), the first long-acting prodrug stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD). METHODS A PubMed search was conducted for English-language articles published up to 16 September 2013 using the following search terms: (lisdexamfetamine OR lisdexamphetamine OR SPD489 OR Vyvanse OR Venvanse OR NRP104 NOT review [publication type]). RESULTS In short-term, parallel… CONTINUE READING
13 Citations
72 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 72 references

Vyvanse (lisdexamfetamine dimesylate) US prescribing information

  • Shire US Inc
  • Revised June 2013. http://pi.shirecontent. com/PI…
  • 2013
Highly Influential
8 Excerpts

Similar Papers

Loading similar papers…